Sutro Biopharma’s 2024 revenue fell to $62 million from $153.7 million in 2023. The company expects its cash runway to last through at least Q4 2026, excluding potential milestone payments.

STRO's valuation remains compelling despite recent market hits, with optimism for a turnaround driven by late-stage clinical trials and strong pipeline potential. Luveltamab tazevibulin shows ...

Sutro Biopharma, Inc. (STRO) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Fintel reports that on March 14, 2025, Wedbush downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from Outperform ...

Sutro Biopharma Inc STRO shares are trading lower by 2.8% to $5.18 during Tuesday’s session after the company announced the pricing of an underwritten offering of 14,478,764 shares of its common ...